A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Qin, Yanan ^a,b   Tian, Hongxia ^c   Wang, Guanming ^a   Lin, Chen ^a   Li, Yangqiu ^a,d  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL PROTEIN ANTIBODY; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; PLASMID VECTOR; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; CANCER VACCINE; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN K 562; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA IMMUNIZATION; GENE EXPRESSION REGULATION; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOSTIMULATION; IN VIVO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CHRONIC MYELOID LEUKEMIA; GENETICS; HUMAN; IMMUNOLOGY; K562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

MUS;

ANIMALS; CANCER VACCINES; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

EID: 84879366583     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/136492     Document Type: Article

References (37)

1. Deininger M. W. N., Goldman J. M., Melo J. V., The molecular biology of chronic myeloid leukemia. Blood 2000 96 10 3343 3356 2-s2.0-0034670036
2. Barnes D. J., Melo J. V., Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006 5 24 2862 2866 2-s2.0-33845664398 (Pubitemid 44953936)
3. Maekawa T., Ashihara E., Kimura S., The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. International Journal of Clinical Oncology 2007 12 5 327 340 2-s2.0-35348866151 10.1007/s10147-007-0699-1 (Pubitemid 47573416)
4. Weisberg E., Manley P. W., Cowan-Jacob S. W., Hochhaus A., Griffin J. D., Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Reviews Cancer 2007 7 5 345 356 2-s2.0-34247470836 10.1038/nrc2126 (Pubitemid 46652483)
5. Davies S. P., Reddy H., Caivano M., Cohen P., Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochemical Journal 2000 351 1 95 105 2-s2.0-0034306450 10.1042/0264-6021:3510095
6. Bain J., McLauchlan H., Elliott M., Cohen P., The specificities of protein kinase inhibitors: an update. Biochemical Journal 2003 371 1 199 204 2-s2.0-0037392942 10.1042/BJ20021535 (Pubitemid 36458094)
7. Yong A. S. M., Keyvanfar K., Eniafe R., Savani B. N., Rezvani K., Sloand E. M., Goldman J. M., Barrett A. J., Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 2008 22 9 1721 1727 2-s2.0-51649108782 10.1038/leu.2008.161
8. Collins R. H. Jr., Shpilberg O., Drobyski W. R., Porter D. L., Giralt S., Champlin R., Goodman S. A., Wolff S. N., Hu W., Verfaillie C., List A., Dalton W., Ognoskie N., Chetrit A., Antin J. H., Nemunaitis J., Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology 1997 15 2 433 444 2-s2.0-2942712161 (Pubitemid 27074209)
9. Weiden P. L., Flournoy N., Thomas E. D., Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. The New England Journal of Medicine 1979 300 19 1068 1073 2-s2.0-0018764352 (Pubitemid 9198740)
10. He L., Feng H., Raymond A., Kreeger M., Zeng Y., Graner M., Whitesell L., Katsanis E., Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunology, Immunotherapy 2001 50 1 31 40 2-s2.0-0035094066 (Pubitemid 32250044)
11. Deeb D., Gao X., Jiang H., Divine G., Dulchavsky S. A., Gautam S. C., Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse. Journal of Experimental Therapeutics and Oncology 2006 5 3 183 193 2-s2.0-33646706342 (Pubitemid 43843829)
12. Zeng Y., Feng H., Graner M. W., Katsanis E., Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003 101 11 4485 4491 2-s2.0-0038466354 10.1182/blood-2002-10-3108 (Pubitemid 36857818)
13. Osman Y., Takahashi M., Zheng Z., Koike T., Toba K., Liu A., Furukawa T., Aoki S., Aizawa Y., Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 1999 13 2 166 174 2-s2.0-0033063104 (Pubitemid 29092648)
14. Sun J., Krouse R. S., Forman S. J., Senitzer D., Sniecinski I., Chatterjee S., Wong K. K. Jr., Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Research 2002 62 11 3175 3183 2-s2.0-0036605994 (Pubitemid 34602411)
15. Pinilla-Ibarz J., Cathcart K., Korontsvit T., Soignet S., Bocchia M., Caggiano J., Lai L., Jimenez J., Kolitz J., Scheinberg D. A., Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000 95 5 1781 1787 2-s2.0-0034161533 (Pubitemid 30120843)
16. + T cells in myeloid malignancies. Haematologica 2011 96 3 432 440 2-s2.0-79952349210 10.3324/haematol.2010.031674
17. Li N., Yu Y., Yu W., Sun Z., Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacology and Immunotoxicology 2011 33 1 211 219 2-s2.0-79551595130 10.3109/08923971003782327
18. Lucansky V., Sobotkova E., Tachezy R., Duskova M., Vonka V., DNA vaccination against bcr-abl-positive cells in mice. International Journal of Oncology 2009 35 4 941 951 2-s2.0-70449434669 10.3892/ijo-00000408
19. Hrusková V., Morávková A., Babiarová K., Ludvíková V., Fric J., Vonka V., Forstová J., Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles. International Journal of Oncology 2009 35 6 1247 1256 2-s2.0-73949131500 10.3892/ijo-00000441
20. Yu M., Finn O. J., DNA vaccines for cancer too. Cancer Immunology, Immunotherapy 2006 55 2 119 130 2-s2.0-28044436084 10.1007/s00262-005-0008-7 (Pubitemid 41683213)
21. Nadal E., Fowler A., Kanfer E., Apperley J., Goldman J., Dazzi F., Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Experimental Hematology 2004 32 2 218 223 2-s2.0-0842330661 10.1016/j.exphem.2003.10.016 (Pubitemid 38177648)
22. Dietz A. B., Litzow M. R., Bulur P. A., Vuk-Pavlović S., Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous TH1 T cells. Cytotherapy 2001 3 2 97 105 2-s2.0-0034997855 10.1080/ 14653240152584505 (Pubitemid 32466094)
23. Greenland J. R., Letvin N. L., Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007 25 19 3731 3741 2-s2.0-34247255391 10.1016/j.vaccine. 2007.01.120 (Pubitemid 46613830)
24. Cen D., Hu G., Zhou Y., Yang L., Chen S., Schmidt C. A., Li Y., Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RAR α and hIL-2 genes. Hematology 2010 15 2 88 95 2-s2.0-77952185345 10.1179/102453310X125833470096589073
25. Conry R. M., LoBuglio A. F., Loechel F., Moore S. E., Sumerel L. A., Barlow D. L., Curiel D. T., A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Therapy 1995 2 1 59 65 2-s2.0-0028853124
26. Roos A., Pavlenko M., Charo J., Egevad L., Pisa P., Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005 62 3 217 223 2-s2.0-12344338245 10.1002/pros.20135 (Pubitemid 40129059)
27. Timmerman J. M., Singh G., Hermanson G., Hobart P., Czerwinski D. K., Taidi B., Rajapaksa R., Caspar C. B., Van Beckhoven A., Levy R., Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Research 2002 62 20 5845 5852 2-s2.0-0037108685 (Pubitemid 35204744)
28. + T cell responses by DNA vaccination. Journal of Molecular Medicine 2003 81 2 91 101 2-s2.0-0037294176 (Pubitemid 36313234)
29. + T-cell responses induced by DNA immunization. Journal of Virology 2000 74 18 8286 8291 2-s2.0-0033850377 10.1128/JVI.74.18.8286-8291.2000 (Pubitemid 30666677)
30. Komschlies K. L., Gregorio T. A., Gruys M. E., Back T. C., Faltynek C. R., Wiltrout R. H., Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. Journal of Immunology 1994 152 12 5776 5784 2-s2.0-0028337496 (Pubitemid 24174157)
31. Mule J. J., Custer M. C., Travis W. D., Rosenberg S. A., Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. Journal of Immunology 1992 148 8 2622 2629 2-s2.0-0026560406
32. Brunda M. J., Luistro L., Warrier R. R., Wright R. B., Hubbard B. R., Murphy M., Wolf S. F., Gately M. K., Antitumor and antimetastatic activity of interleukin 12 against murine tumors. Journal of Experimental Medicine 1993 178 4 1223 1230 2-s2.0-0027239503 (Pubitemid 23277355)
33. Pasquini S., Xiang Z., Wang Y., He Z., Deng H., Blaszczyk-Thurin M., Ertl H. C. J., Cytokines and costimulatory molecules as genetic adjuvants. Immunology and Cell Biology 1997 75 4 397 401 2-s2.0-0030968562 (Pubitemid 27408048)
34. Irvine K. R., Rao J. B., Rosenberg S. A., Restifo N. P., Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Journal of Immunology 1996 156 1 238 245 2-s2.0-0030022796 (Pubitemid 26006969)
35. He X., Tsang T. C., Zhang T., Luo P., Harris D. T., Antigen epitope-expressing cytokines for DNA immunization. Vaccine 2005 23 16 1966 1972 2-s2.0-14244268426 10.1016/j.vaccine.2004.10.010 (Pubitemid 40289068)
36. Seung Woo Lee S. W. L., Jae Ho Cho J. H. C., Young Chul Sung Y. C. S., Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. Journal of Virology 1998 72 10 8430 8436 2-s2.0-0031664801
37. Chen W., Peace D. J., Rovira D. K., You S.-G., Cheever M. A., T-cell immunity to the joining region of p210(BCR-ABL) protein. Proceedings of the National Academy of Sciences of the United States of America 1992 89 4 1468 1472 2-s2.0-0026518291